Ovarian Function during Puberty in Girls with Type 1 Diabetes Mellitus: Response to Leuprolide

Ethel Codner, Dennis Mook-Kanamori, Rodrigo A. Bazaes, Nancy Unanue, Hugo Sovino, Francisca Ugarte, Alejandra Avila, German Iníguez, and Fernando Cassorla

Institute of Maternal and Child Research (E.C., D.M.K., R.A.B., N.U., H.S., G.I., F.C.), School of Medicine, University of Chile, 836-0160 Santiago, Chile; Hospital Exequiel G. Cortés (F.U.), 891-0108 Santiago, Chile; and Hospital San Borja Arriarán (A.A.), 836-0160 Santiago, Chile

Context: An increased prevalence of polycystic ovary syndrome (PCOS) has been reported in adult women with type 1 diabetes mellitus (DM1). We investigated whether these hormonal abnormalities begin during puberty by evaluating the ovarian steroidogenic response to leuprolide acetate.

Methods: We studied 56 adolescent girls with DM1 (aged 12.3 ± 0.2 yr) and 64 healthy girls (C) (aged 11.9 ± 0.2 yr) up to 2 yr post menarche, matched by age, body mass index, and pubertal development. We evaluated anthropometrical data and Ferriman-Gallway score and performed a leuprolide test (500 μg sc) to study ovarian function. Ovarian volume was determined by transabdominal ultrasonography.

Results: We found five DM1 but no C girls with abnormally located terminal hair (Fisher’s exact, P < 0.05). Free androgen index increased throughout puberty in girls with DM1 (ANOVA, P < 0.0001), which was associated with a decrease in SHBG levels in girls with DM1 (ANOVA, P < 0.0001). Stimulated 17OH progesterone (17OHProg) increased throughout puberty only in girls with DM1 (ANOVA, P < 0.01). Girls with DM1 at Tanner stage 5 had higher stimulated LH to FSH ratio, testosterone, and 17OHProg levels than girls at Tanner stage 4. In contrast, in C girls the stimulated testosterone, 17OHProg, and LH to FSH ratio were similar at Tanner stages 4 and 5. Ovarian volumes and uterine length were larger in girls with DM1 (analysis of covariance, P < 0.05).

Conclusions: These data suggest that patients with DM1 have differences in ovarian steroidogenic response to leuprolide, compared with C girls during puberty. Future studies in young women should clarify whether these findings are related to the pathogenesis of hyperandrogenism later in life (J Clin Endocrinol Metab 90: 3939–3945, 2005)

POLYCYSTIC OVARY SYNDROME (PCOS) is frequently associated with insulin resistance and type 2 diabetes mellitus (1). Recently an increased prevalence of PCOS has been observed in adult women with type 1 diabetes mellitus (DM1) as well. Escobar-Morreale et al. (2) evaluated 68 adult women with DM1 and observed that 18.8% had PCOS and 20% had hirsutism without other endocrinological abnormalities. An onset of DM1 before menarche was a risk factor for the subsequent development of hyperandrogenic disorders (2), suggesting that the presence of DM1 during adolescence may play a critical role in the pathogenesis of hyperandrogenism.

It has been suggested that the use of exogenous insulin to treat DM1 in these patients may contribute to the development of PCOS. Insulin is administered in a nonphysiological fashion because it is injected sc and is absorbed into the systemic circulation (3), potentially stimulating the synthesis of androgens by the ovaries (4). In vitro studies have shown that insulin acts synergically with LH to stimulate the synthesis of testosterone by ovarian thecal cells (4). An additional pathogenic mechanism might be the exacerbated insulin resistance observed in patients with DM1 during puberty (5), which has been proposed to play a role in the pathogenesis of PCOS (6).

PCOS is the result of an abnormal regulation of steroidogenesis, specifically of androgen secretion by the ovary. Provocative tests using GnRH analogs have shown that the hyperandrogenism has an ovarian source in most cases (7, 8). Such alteration may precede the development of clinical manifestations of PCOS and has been termed functional ovarian hyperandrogenism (FOH) (8).

Clinical manifestations of PCOS usually arise during the perimenarchal period (9), but earlier manifestations of this syndrome, such as precocious pubarche, have been observed before puberty (10). It is not known, however, whether a similar sequence of events occurs in girls with DM1. Therefore, the purpose of this study was to determine whether the hyperandrogenism described in some adult women with DM1 is already detectable during puberty. With this aim, we evaluated the hormonal response to a GnRH analog in a rather large group of pubertal girls with DM1 and compared their response with a carefully matched group of normal girls in a cross-sectional study.

Subjects and Methods

Subjects

Pubertal girls (n = 56) with DM1 were recruited from four public hospitals in Santiago, Chile. Girls had breast development Tanner stages...
Two circumferences. Measurement was obtained at the maximum perimeter at the level of the margin and the iliac crest in the standing position. The hip circumference was measured to the nearest 0.5 cm, using a flexible tape. The simplified formula for a prolate ellipsoid (19). The larger ovary was used to evaluate ovarian size.

The protocol was approved by the respective institutional review boards. All parents signed informed consents and girls gave their assent before entering the study.

**Hormone assays**

Serum testosterone, androstenedione, 17OHProg, and DHEAS were measured by competitive specific binding RIAs (Diagnostic System Laboratories, Webster, TX); interassay coefficients of variation (CVs) were 8.1, 8.9, 7.3, and 7.7%, respectively; intraassay CVs were 5.3, 4.2, 7.7, and 5.3%, respectively (20). HbA1c levels were measured using a commercially available automatic system (DACO 2000, Bayer Diagnostics, Tarrytown, NY).

Serum LH, FSH, and SHBG levels were measured by immunoradiometric assays from Diagnostic System Laboratories. Intraassay CVs were 6.5% for LH, 3.6% for FSH, and 5.3% for SHBG. Interassay CVs were 7.6% for LH, 6.2% for FSH, and 6.9% for SHBG.

Serum estradiol, insulin, and C-peptide levels were determined by RIAs as previously described (20, 21).

**Statistical analysis**

Clinical and laboratory data are shown as mean ± SEM. Comparisons of means between the two groups (girls with DM1 and C) for each Tanner stage were performed using the Mann-Whitney U test. Differences within each group among the various Tanner stages were assessed by one-way ANOVA, followed by the least significant differences test for multiple comparisons. Interaction between Tanner stage and group was estimated by full-fact analysis of covariance (ANCOVA). The effect of BMI, insulin doses, and metabolic control on SHBG and stimulated 17OHProg levels was also evaluated using ANCOVA. Duration of disease was not included in the analyses because it showed strong collinearity with age and Tanner stage. Differences in proportions between the two groups were evaluated using Fisher’s exact test. Results are expressed as mean age ± SEM. All statistical calculations were run on SPSS for Windows (version 10.0; SPSS, Inc., Chicago, IL). P < 0.05 was considered statistically significant.

**Results**

Fifty-six girls with DM1 (aged 12.3 ± 0.2 yr) and 64 girls (aged 11.9 ± 0.2 yr) were studied. Their clinical characteristics are shown in Table 1. The proportion of postmenarchal girls in each group was similar (20 girls with DM1 and 14 C girls, P > 0.05), and their gynecological age was 1.2 ± 0.2 yr in girls with DM1 and 1.1 ± 0.2 yr in C (P = 0.86, Mann-Whitney U test).

Six girls with DM1, but no C, had a Ferriman-Gallway score equal to or greater than 5 (range 5–8, Fisher’s exact test,

**TABLE 1.** Clinical and anthropometric characteristics of girls with DM1 and C as well as metabolic control in girls with DM1 according to Tanner stage (T)

| Tanner 2 | Tanner 3 | Tanner 4 | Tanner 5 |
|---------|---------|---------|---------|
|         | DM1     | C       | DM1     | C       | DM1     | C       | DM1     | C       |
| n       | 14      | 15      | 14      | 15      | 12      | 15      | 16      | 19      |
| Age (yr)| 10.8 ± 0.3 | 10.4 ± 0.3 | 11.7 ± 0.2 | 11.3 ± 0.3 | 12.6 ± 0.3 | 12.1 ± 0.3 | 13.9 ± 0.3 | 13.4 ± 0.2 |
| BMI SDS | -0.2 ± 0.2 | 0.4 ± 0.2 | 0.1 ± 0.2 | 0.3 ± 0.4 | 0.3 ± 0.2 | 0.7 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.2 |
| Height SDS | -0.5 ± 0.2 | -0.4 ± 0.3 | -0.2 ± 0.3 | -0.4 ± 0.3 | 0.0 ± 0.3 | 0.3 ± 0.2 | -0.5 ± 0.3 | -0.3 ± 0.2 |
| Waist to hip ratio | 80.1 ± 1.2 | 89.7 ± 1.3 | 78.8 ± 1.2 | 83.3 ± 1.2 | 81.7 ± 1.8 | 82.1 ± 1.3 | 79.0 ± 1.3 | 80.2 ± 1.0 |
| DM1 duration (yr) | 4.0 ± 0.7 | 3.3 ± 0.8 | 4.8 ± 1.0 | 5.1 ± 0.8 | 9.9 ± 0.6* | 9.2 ± 0.5 | 1.2 ± 0.1* | 1.0 ± 0.1 |
| HbA1c (%) | 8.9 ± 0.5 | 8.0 ± 0.4 | 9.1 ± 0.6* | 9.2 ± 0.5 | 0.9 ± 0.1 | 0.8 ± 0.1 | 1.2 ± 0.1* | 1.0 ± 0.1 |

Data are shown as mean ± SEM. SDS, SD score.

* P < 0.05 DM1 T3 vs. C T3 (Mann-Whitney U).

* P < 0.05 DM1 T4 vs. DM1 T3 (ANOVA).

* P < 0.05 DM1 T4 vs. DM1 T2–3 and P < 0.01 DM1 T4 vs. DM1 T2 (ANOVA).
P < 0.01). In contrast, all C girls showed Ferriman-Gallway scores of either 0 or 1. The age range of the hirsute DM1 patients was 8.5–14.3 yr, two were in Tanner 2, and the remaining were in Tanner 5. Three of the hirsute DM1 girls exhibited increased testosterone levels and FAI. Acne was observed in a similar proportion in both groups of girls (11 girls in each group had some acne, being moderate to severe in three DM1 girls and two C, P > 0.05). Seven C and two DM1 girls had a family history of PCOS, but the clinical and laboratory findings were similar whether these patients were included or excluded. Thus, it was decided to include these patients in the final analyses.

**Gonadotropins** (Table 2 and Fig. 1). Basal FSH levels increased throughout puberty only in DM1 girls (ANOVA, P < 0.05). Basal LH to FSH ratio increased in both C and DM1 girls during puberty. Stimulated LH to FSH also increased in both groups up to Tanner stage 4, but this ratio increased further in Tanner 5 DM1 girls only (6.8 ± 2.1 vs. 2.5 ± 0.4, ANOVA, P < 0.05). In contrast, the stimulated LH to FSH ratio was similar in Tanner 4 and 5 C girls.

**Steroids and SHBG**. Basal steroid levels are shown in Table 2.

| Steroid          | Tanner 2 | Tanner 3 | Tanner 4 | Tanner 5 |
|------------------|----------|----------|----------|----------|
| DHEAS (ng/ml)    | 0.2 ± 0.1| 0.9 ± 0.1| 1.2 ± 0.2| 1.9 ± 0.2|
| FAI              | 1.2 ± 0.2| 2.2 ± 0.4| 3.1 ± 0.5| 6.4 ± 1.1|
| SHBG (nmol/liter)| 57.0 ± 29.9| 50.3 ± 29.9| 40.6 ± 3.5| 38.3 ± 3.4|
| Testosterone (ng/dl)| 20.3 ± 3.2| 28.1 ± 4.1| 33.9 ± 5.4| 50.8 ± 5.8|
| Androstenedione (ng/ml)| 1.2 ± 0.1| 1.2 ± 0.2| 1.9 ± 0.2| 2.1 ± 0.2|

In girls with DM1, SHBG levels were significantly lower than in C at Tanner stages 2 and 3 (Mann Whitney U, P < 0.05). Basal and stimulated estradiol levels increased through puberty only in C girls (ANOVA, both P < 0.01). Stimulated estradiol levels were higher in C than DM1 girls at Tanner stage 4 (Mann-Whitney U, P < 0.05).

Steroids levels after the administration of leuprolide acetate are shown in Fig. 2. Stimulated testosterone levels were higher in girls with DM1 at Tanner stage 5 than those at Tanner stages 2–4 (ANOVA, P < 0.05). Accordingly, stimulated 17OHProg was significantly higher in girls with DM1 at Tanner stage 5 than at Tanner stages 2–4 (T5 vs. T2: P < 0.0001, T5 vs. T3: P < 0.01, T5 vs. T4: P < 0.05). In contrast, stimulated 17OHProg and testosterone levels did not increase throughout puberty in C girls. Stimulated and basal 17OHProg were higher in Tanner 2 and 4 C girls than girls with DM1 (Mann-Whitney U, both P < 0.05). ANCOVA indicated that the interaction between Tanner stage and diabetes on stimulated 17OHProg was significant (P < 0.01). When DM1 girls were analyzed separately, stimulated levels of 17OHProg were related to Tanner stage only (ANOVA, P < 0.01) but not to BMI, insulin dose, or metabolic control. Stimulated A2 levels increased through puberty in both groups, and were higher in DM1 than in C at Tanner stage 2 only (Mann-Whitney U, P < 0.05).

**Transabdominal ultrasonography** (Fig. 3). Ovarian volume, corrected for Tanner stage, was greater in DM1 than C girls (ANOVA, P < 0.05). Uterine length increased through puberty in DM1 and C girls, being larger in DM1 girls, even after adjusting for Tanner stage (ANOVA, P < 0.05).

**TABLE 2.** Basal steroids and gonadotropins in girls with DM1 and controls (C) according to Tanner stage (T)

| Steroid          | Tanner 2 | Tanner 3 | Tanner 4 | Tanner 5 |
|------------------|----------|----------|----------|----------|
| DHEAS (ng/ml)    | 0.2 ± 0.1| 0.9 ± 0.1| 1.2 ± 0.2| 1.9 ± 0.2|
| FAI              | 1.2 ± 0.2| 2.2 ± 0.4| 3.1 ± 0.5| 6.4 ± 1.1|
| SHBG (nmol/liter)| 57.0 ± 29.9| 50.3 ± 29.9| 40.6 ± 3.5| 38.3 ± 3.4|
| Testosterone (ng/dl)| 20.3 ± 3.2| 28.1 ± 4.1| 33.9 ± 5.4| 50.8 ± 5.8|
| Androstenedione (ng/ml)| 1.2 ± 0.1| 1.2 ± 0.2| 1.9 ± 0.2| 2.1 ± 0.2|

Data are shown as mean ± SE. To convert units to SI: testosterone (nanograms per deciliter) × 0.0347 = nanomoles per liter; androstenedione (nanograms per milliliter) × 3.49 = nanomoles per liter; DHEAS (nanograms per milliliter) × 0.0027 = nanomoles per liter; estradiol (picograms per milliliter) × 3.67 = picomoles per liter; 17OHProg (nanograms per milliliter) × 3.03 = nanomoles per liter.

* P < 0.0001 DM1 T5 vs. DM1 T2; P < 0.001 DM1 T5 vs. DM1 T3; P < 0.01 DM1 T5 vs. DM1 T4 (ANOVA).
* P < 0.0001 DM1 T2 vs. C T2 (Mann-Whitney U).
* P < 0.0001 DM1 T3 vs. C T3 (Mann-Whitney U).
* P < 0.0001 DM1 T5 vs. T2; P < 0.0001 DM1 T5 vs. T3 (ANOVA).
* P < 0.05 DM1 T5 vs. DM1 T2 (ANOVA).
* P < 0.05 DM1 T3 vs. DM1 T2 (ANOVA).
* P < 0.01 DM1 T5 vs. DM1 T2; P < 0.05 DM1 T5 vs. DM T3 (ANOVA).
* P < 0.05 DM1 T5 vs. C T2 (ANOVA).
* P < 0.05 DM1 T2 vs. C T2 and DM1 T3 vs. C T3 (Mann-Whitney U).
* P < 0.05 DM T4 vs. C T4 (Mann-Whitney U).
Discussion

We report a comprehensive study of ovarian function in a large group of pubertal girls with DM1, up to 2 yr post-menarche, compared with a control group carefully matched by Tanner stage and BMI. Our data suggests that DM1 may affect ovarian steroidogenic response to leuprolide, a GnRH analog, during puberty, which might play a role in the subsequent development of ovarian hyperandrogenism and PCOS.

It has become increasingly clear that PCOS results from by a dysregulation of steroid biosynthesis, which may become manifested as FOH, defined as an abnormal 17OHProg response to GnRH stimulation (22). In some cases FOH may precede clinical hyperandrogenism (23). Our data show that DM1 may influence the ovarian steroidogenic response to leuprolide acetate, with increasing levels of the 17OHProg throughout puberty. DM1 girls attained maximum 17OHProg levels at the end of puberty, in contrast to C girls who achieved a maximum response to leuprolide acetate during the middle stages of puberty, as previously reported (17). In accordance with our results, Virdis et al. (24) found in a group of nine oligomenorrheic postpubertal adolescents with DM1 an elevated 17OHProg response to leuprolide, suggesting the presence of FOH.

In our study, stimulated 17OHProg levels in DM1 girls were not related to BMI, HbA1c, or daily insulin dose. It has been proposed that the increased ovarian steroidogenic activity in women with DM1 may result from the supraphysiological doses of insulin required to achieve optimal metabolic control. Furthermore, exogenous insulin reaches the systemic circulation in a nonphysiological fashion (3) and may bind insulin and IGF-I receptors in the ovary (25, 26). In vitro, insulin may act in concert with gonadotropins on the ovary (27) and may also have direct effects on the activity of steroidogenic enzymes. However, it is not known what proportion of the insulin dose administered to girls with DM1 effectively reaches the ovaries. Hence, we cannot exclude an effect of exogenous insulin in our group of girls with DM1.

In addition to an altered response to the leuprolide test, an increase in FAI was observed in girls with DM1. This could be particularly relevant because a recent consensus proposes the FAI as one of the diagnostic criteria for PCOS (28). However, total testosterone levels were similar in DM1 and C at all Tanner stages. Meyer et al. (29) found elevated testosterone levels in pubertal girls with DM1 only at Tanner stage 5, which is in accordance with our finding of an increased FAI at the end of puberty in girls with DM1.

The increase in FAI in girls with DM1 may be explained at least in part by decreasing SHBG levels during puberty. ANCOVA showed that this latter finding was related to BMI, as previously described (30, 31). Previous studies have shown that DM1 girls increase their fat mass (32) and their waist to hip ratio (33) during puberty. Although the C and DM1 groups were matched for BMI, we cannot exclude that differences in fat mass associated with DM1 may explain the changes in SHBG levels in our population. It is unlikely that the SHBG levels were affected by insulin dose use, however, because ANCOVA analysis showed that SHBG levels were not related to insulin dose or metabolic control.

Girls with DM1 exhibited increasing FSH levels during puberty. This was not associated with increasing basal or stimulated levels of estradiol, suggesting that ovarian function is influenced by the diabetic condition, as shown in adult
FIG. 3. Transabdominal ultrasonography in DM1 and C girls according to Tanner stage (T). Broken line and triangles, C girls; continuous line and squares, DM1 girls. Data are shown as average ± SE. A, Ovarian volume. Both ovaries were measured and the larger one is described in the figure. *, Ovarian volume in DM1 larger than in C adjusted by Tanner stage, $P < 0.05$ (ANCOVA). B, Uterine length. *, DM1 vs. C adjusted by Tanner stage, $P < 0.05$ (Mann-Whitney U).

FIG. 2. Steroid levels after the stimulation with leuprolide acetate 500 $\mu$g sc in DM1 and C girls according to Tanner stage (T). Stimulated testosterone, 17OHProg, estradiol, and androstenedione were obtained 24 h after the injection with leuprolide acetate. Broken line and triangles, C girls; continuous line and squares, DM1 girls. Data are shown as average ± SEM. A, Stimulated 17OHProg levels. +, DM1 T5 vs. DM1 T 2–4, $P < 0.05$ (ANOVA). *, DM1 T5 vs. C T2, $P < 0.05$ (Mann-Whitney U) and DM1 T4 vs. C T4, $P < 0.05$ (Mann-Whitney U). B, Stimulated testosterone levels. +, DM1 T5 vs. DM1 T2–5, $P < 0.05$ (ANOVA). †, C T4 vs. C T2, $P < 0.05$ (Mann-Whitney U). C, Stimulated androstenedione levels. *, DM1 T2 vs. C T2, $P < 0.05$ (Mann-Whitney U). D, Stimulated estradiol levels. +, C girls showed different estradiol levels at all T stages, $P < 0.01$ (ANOVA). *, DM1 T4 vs. C T4, $P < 0.05$ (Mann-Whitney U). To convert units to SI: testosterone (nanograms per deciliter) × 0.0347 = nanomoles per liter; androstenedione (nanograms per milliliter) × 3.49 = nanomoles per liter; DHEAS (nanograms per milliliter) × 0.0027 = nanomoles per liter; estradiol (picograms per milliliter) × 3.67 = picomoles per liter; 17OHProg (nanograms per milliliter) × 3.03 = nanomoles per liter.

Codner et al. Ovarian Function in Pubertal Girls with Type 1 Diabetes J Clin Endocrinol Metab, July 2005, 90(7):3939–3945

Downloaded from https://academic.oup.com/jcem/article-abstract/90/7/3939/2837231 by guest on 25 July 2018
males with DM1 (34). These data suggesting that DM1 may influence ovarian function by the end of puberty are in agreement with our recent observations regarding pubertal development in girls with DM1 (33). We observed that girls with DM1 show a delay in pubertal development by the final stages of puberty, and this was associated with increasing BMI and a lack of the normal decrease in the waist to hip ratio, continuing to deteriorate 2 yr after menarche. Thus, girls with DM1 appear to show differences in pubertal development and ovarian function during late puberty, compared with C.

Ovarian volume has also been proposed as a diagnostic criterion of PCOS (28). To our knowledge, the larger ovarian volume observed in pubertal patients with DM1 has not been reported previously. This finding may represent an early sign of PCOS, as demonstrated by a longitudinal assessment of ovarian size in girls with irregular menses (35). Venturroli et al. (35) showed that enlarged ovaries in perimenarchal girls may persist over time and may be associated with subsequent hyperandrogenism.

We observed subtle evidence of clinical hyperandrogenism as slight hirsutism in 10% of pubertal girls with DM1. In contrast, our C girls did not show any evidence of abnormal hair growth. Moreover, the prevalence of hirsutism in these girls was greater than the reported 5% in adult Chilean women (14). Half of these girls had elevated androgen levels, but three had normal steroid concentrations, including normal FAL, suggesting that some girls with DM1 had idiopathic hirsutism. The previous study by Escobar-Morreale (2) showed a mean Ferriman-Gallway score of 11 in 17% of adult women with DM1, being less severe than in hyperandrogenic women without DM1 (36). Careful follow-up of our patients will clarify whether this slight hirsutism in 10% of pubertal girls with DM1 may persist over time and may be associated with subsequent hyperandrogenism.

In summary, adolescents with DM1 show increasing levels of 17OHPreg after stimulation with leuprolide acetate during late puberty, associated with decreasing levels of SHBG and increasing FAL. Moreover, a higher prevalence of hirsutism during puberty was observed in girls with DM1, compared with C. These data suggest that patients with DM1 have differences in ovarian steroidogenesis, compared with normal girls during puberty. Future studies in young women should clarify whether these findings are related to the pathogenesis of hyperandrogenism later in life.

Acknowledgments

Received January 24, 2005. Accepted April 20, 2005.

Address all correspondence and requests for reprints to: Ethel Codner, M.D., Institute of Maternal and Child Research, School of Medicine, University of Chile, Casilla 226-3, Santiago, Chile. E-mail: ecodner@med.uchile.cl.

This work was supported in part by Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) Grant 1050452 (to E.C.).

References

1. Legro RS, Kunselman AR, Dodson WC, Dunai A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169

2. Escobar-Morreale HF, Roldan B, Barrio R, Alonso M, Sancho J, de la Calle H, Garcia-Robles R 2000 High prevalence of the polycystic ovary syndrome and insulin resistance in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 85:4182–4187

3. Bolli GB 2001 Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 109(Suppl 2):S17–S332

4. Cara JE, Rosenfield RL 1988 Insulin-like growth factor I and insulin potentiate lutenezizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 123:733–739

5. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV 1986 Imprinted insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 315:215–219

6. Dunai A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800

7. Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS 2004 Distribution of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab 13:1285–1289

8. Ehrmann DA, Barnes RB, Rosenfield RL 1995 Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen enzymatic activity. Endocr Rev 16:549–555

9. Baumann EE, Rosenfield RL 2002 Polycystic ovary syndrome in adolescence. Endocrinologist 12:333–348

10. Ibanez L, de Zegher F, Potau N 1998 Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest 21:558–566

11. Marshall WA, Tanner JM 1969 Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291–297

12. Ferriman D, Gallway JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447

13. Hatch R, Rosenfield RL, Kim MH, Tredway D 1981 Hirsutism: implications, etiology, and management. J Obstet Gynecol Neonatol 140:815–830

14. Tellez R, Frenkel J 1995 Clinical evaluation of body hair in healthy women. Rev Med Chil 123:1349–1354

15. Gordon CM 1999 Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. Pediatr Clin North Am, 48:519–548

16. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roache AF, Johnson CL 2002 Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60

17. Ibanez L, Potau N, Zampolli M, Street ME, Carrascosa A 1997 Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. J Pediatr 130:269–275

18. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672

19. Swanson M, Sauerbrei EE, Cooperberg PL 1981 Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 9:219–222

20. Codner E, Okuma C, Iniguez G, Boric MA, Avila A, Johnson MC, Cassorla FG 2004 Molecular study of the 3p-hydroxysteroid dehydrogenase gene type II in patients with hyperandrogenemia. J Clin Endocrinol Metab 89:589–596

21. Bazaes RA, Salazar TE, Pittaluga E, Pena V, Alegria A, Iniguez G, Ong KK, Alegria A, Vicens-Calvet E 1993 Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76:1599–1603

22. Virdis R, Zampolli M, Street ME, Vanelli M, Potau N, Terzi C, Ghizzi M, Ibanez L 1997 Ovarian 17α-hydroxyprogesterone responses to GnRH analog testing in oligomenorrheic insulin-dependent diabetic adolescents. Eur J Endocrinol 136:624–629

23. Poretsky L, Smith D, Seibel M, Pazianos A, Moses AC, Flier JS 1984 Specific insulin binding sites in human ovary. Clin Endocrinol Metab 59:809–811

24. Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS 1985 Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. J Clin Endocrinol Metab 61:728–734

25. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ 1986 Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 62:904–910

26. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

27. Meyer K, Deutscher J, Anil M, Berthold A, Barsch M, Kiess W 2000 Serum
androgen levels in adolescents with type 1 diabetes: relationship to pubertal stage and metabolic control. J Endocrinol Invest 23:362–368

30. De Simone M, Verrotti A, Iughetti L, Palumbo M, Farello G, Di Cesare E, Bernabei R, Rosato T, Lozzi S, Criscione S 2001 Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone-binding globulin levels in massively obese adolescent girls. J Endocrinol Invest 24:438–444

31. Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, Pugeat M 2003 Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:3626–3631

32. Ahmed ML, Ong KK, Watts AP, Morrell DJ, Preece MA, Dunger DB 2001 Elevated leptin levels are associated with excess gains in fat mass in girls, but not boys, with type 1 diabetes: longitudinal study during adolescence. J Clin Endocrinol Metab 86:1188–1193

33. Codner E, Barrera A, Mook-Kanamori D, Bazaes RA, Unanue N, Gaete X, Avila A, Ugarte F, Torrealba I, Perez V, Panteon E, Cassorla F 2004 Ponderal gain, waist-to-hip ratio, and pubertal development in girls with type-1 diabetes mellitus. Pediatr Diabetes 5:182–189

34. van Dam EW, Dekker JM, Lentjes EG, Romijn FP, Smulders YM, Post WJ, Romijn JA, Kranse HM 2003 Steroids in adult men with type 1 diabetes: a tendency to hypogonadism. Diabetes Care 26:1812–1818

35. Venturoli S, Forza E, Fabbrini R, Pluchinotta V, Ruggeri S, Macrelli S, Paradisi R, Flaminghi C 1995 Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 38:974–980

36. Roldan B, Escobar-Morreale HF, Barrio R, de La Calle H, Alonso M, Garcia-Robles R, Sancho J 2001 Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care 24:1297–1299

37. Philpott MP, Sanders DA, Kealey T 1994 Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations in vitro. J Invest Dermatol 102:857–861

38. Deplewnski D, Rosenfield RL 2000 Role of hormones in pilosebaceous unit development. Endocr Rev 21:363–392

Erratum

In the article “Metformin Administration versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial” by S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, and F. Zullo (The Journal of Clinical Endocrinology & Metabolism 89:4801–4809), errors appear in one author’s institutional affiliation and in data reported in Tables 2 and 3.

On the title page (page 4801), the correct affiliation of Dr. Luciano Giovanni Nardo is Department of Obstetrics and Gynecology, Wexham Park Hospital, Slough, UK.

In the Abstract (page 4801, lines 18–20), the correct data for ovulation rate in group B is 53.2%, whereas the correct data for pregnancy, abortion, and live-birth rates for group A are 21.8%, 9.3%, and 86.0%, respectively.

In Results (page 4805, right column, lines 2–16), the correct data are: 197 as total number of cycles in group A; 53.2% as ovulation rate in group B, 21.8%, 9.3%, and 86.0% as pregnancy, abortion, and live-birth rates for group A, respectively; 79.6% (43/54) as cumulative pregnancy rate for group A; 3 of 11 as patients of group A having regular ovulatory menstrual cycles at the end of the study. In the Table 2 (page 4805), the correct data are 25/54 (46.3), 23/46 (50.0), 20/36 (55.6), 17/26 (65.4), 13/20 (65.0), 10/15 (66.7) for the ovulation rates of group A during the six cycles of treatment, while for the pregnancy rates of group A during the 3rd, 4th, 5th, and 6th cycle the respective correct data are 10/36 (27.8), 6/26 (23.1), 5/20 (25.0), and 4/15 (26.7); all comparisons between two groups are not significant. In the Table 3 (page 4805), the correct data are 108/197 (54.8), 43/197 (21.8), 4/43 (9.4), and 37/43 (86.0), respectively, for ovulation, pregnancy, abortion, and live-birth rates in group A.

The authors regret the errors.

*The Editors appreciated the assistance of E. M. Kolibianakis, E. G. Papanikolaou, and B. C. Tarlatzis for bringing these errors to the Journal and authors’ attention.

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.